DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder

Information source: Seoul National University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Attention Deficit Hyperactivity Disorder

Intervention: Methylphenidate (Drug)

Phase: N/A

Status: Completed

Sponsored by: Seoul National University

Official(s) and/or principal investigator(s):
Jae-Won Kim, MD., PhD., Principal Investigator, Affiliation: Seoul National University and Seoul National University Hospital


The aims of the current study are to examine gene-environment interactions associated with norepinephrine (NE) system genes (ADRA2A, SLC6A2) in ADHD, and to evaluate whether genetic changes in norepinephrine pathway are associated with differences in functional connectivity of white matter fiber tracts, as measured by diffusion tensor imaging (DTI). Furthermore, this study aims to examine neurobiological markers, such as intermediate neuroimaging phenotypes or neuropsychological endophenotypes associated with the pathophysiology of ADHD. Through evaluating drug responses and side effects with the associated measures of clinical, neuropsychological and neuroimaging characteristics, investigators would like to investigate predictors of treatment response associated with NE system genes in ADHD.

Clinical Details

Official title: Gene-environment Interactions and Brain Functional Connectivity Associated With Norepinephrine System Genes in Attention Deficit Hyperactivity Disorder

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Change From Baseline ADHD Rating Scale-IV Scores at 8 Weeks

Secondary outcome: Clinical Global Impression-Improvement Scale at 8 Weeks


Minimum age: 6 Years. Maximum age: 18 Years. Gender(s): Both.


Inclusion Criteria:

- Clinical diagnosis of Attention-deficit Hyperactivity Disorder

- 6-18 years old

Exclusion Criteria:

- History of neurological diseases, including convulsive disorders or brain damage

- IQ below 70

- Pervasive developmental disorder (autism)

- Language difficulties or learning disorders (reading disorders, mathematics disorders

and disorders of written expression).

- Tourette's syndrome

- Bipolar disorder

- Psychosis

Locations and Contacts

Additional Information

Starting date: May 2010
Last updated: November 26, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017